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ABSTRACT
The initial signal for triggering human parturition might be fetal but of trophoblastic origin. Con-
comitantly, this placental signal would have as its target not only the uterus but also the fetus by
activating its hypothalamo-pituitary-adrenocortical axis. The latter would represent a second fetal
signal which, at the fetomaternal interface, would amplify and define in time the mechanisms
responsible for the onset of labor, implying changes in the myometrial and cervical extracellular
matrix associated with the accession of the contractile phenotype for myometrial cells. At each
phase of these processes in the utero-feto-placental system, the nature of these signals remains to be
identified. Is there a single substance, or rather, and more likely, a combination of several?
We appear to be in the presence of dynamic systems of a neuro-immuno-hormonal type which
are difficult to describe. Nevertheless, steroid hormones appear to coordinate their successive
equilibriums until they become irreversible. Such irreversibility constitutes the essential sign of
parturition. Infect. Dis. Obstet. Gynecol. 5:98-105, 1997. (C) 1997 Wiley-Liss, Inc.
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the act of "bringing a child into the
world is one of the essential keys to life and
to the survival of the species, we cannot help but
be amazed even today by the fact that most of the
physiological mechanisms of human parturition re-
main to be elucidated. Giving birth is not a trivial
act. Indeed, the pathologies associated with it,
whose etiologies remain poorly understood, can ex-
pose both mother and child to varying types of
grave complications. Premature birth, for instance,
is an important unsolved health problem.
One of the reasons why the processes of human
parturition remain to some extent enigmatic is that
results of research utilizing animal models, which
can then be transposed to humans, are, in fact, very
rare. Indeed, there exists extreme species diversity,
especially in endocrine balance, which conditions
the maintenance of gestation. In women, one par-
ticularity would appear to lie in the absence of a
correlation between the evolution of available pa-
rameters, such as the plasma level of steroid hor-
mones or of many other effectors of uterine activ-
ity, and the onset of labor. In this respect, it is only
recently that we have became aware of the speci-
ficity of the human species, as current data reveal a
multitude of pertinent factors, be they genetic, hor-
monal or environmental. This complexity, also pre-
sent in the mechanisms of action of these factors,
has for the moment escaped any simplifying prin-
ciple, whatever the level of analysis of the biologi-
cal systems which are targets in the maternal-fetal
system.
Nevertheless, although experimentation is lim-
ited by considerations of an ethical or practical na-
ture, the availability of molecular biological tech-
niques and of selective pharmacological tools, and
the development ofhuman cell models in the same
way as those enabling better understanding of the
different components of uterine contraction,
should facilitate an approach to this intricacy.
The initial question raised is that of the hor-
monal determination of parturition. The second,
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upon which we will place special emphasis, con-
cerns the molecular mechanisms which, in the
uterus, underlie the two phenomena which charac-
terize parturition: the onset of regular, rhythmic
myometrial contractions and dilatation of the cer-
vix.
HORMONAL DETERMINATION
OF PARTURITION
Much data has been obtained concerning the
mechanisms involved in the onset of parturition in
several animal species. Nonetheless, it must be
admitted that some of these data have had the ef-
fect of momentarily preventing other approaches in
humans. The most striking example is that of the
ewe, with the discovery of an initial signal from the
fetal brain leading to a drop in placental production
of progesterone (which blocks uterine excitability)
and an increase in production of estrogens (which
promote uterine contractility), z For several years, a
number of groups vainly sought the existence of
identical mechanisms in the human species. At
birth, the fetus, depending on the species, is con-
fronted with extremely varied situations necessitat-
ing different competences. Its survival depends
upon its degree of maturation in the broad sense of
that term, since it can involve different functions.
In the human species, where the fetus confronts
extra-uterine life in a state of relative immaturity
and dependence, a fetal signal is difficult to iden-
tify. In anencephalic fetuses, parturition occurs in a
natural manner at term, but is slightly more dis-
persed in time than in normal fetuses. While a role
for fetal membranes has been suggested, based on
their capacity to locally control the metabolism of
steroid hormones, prostaglandins and cytokines,
studies are currently focusing on the placenta and
in particular on its endocrine tissue, the tropho-
blast. One of the characteristics of this tissue is not
only its extraordinary capacity for synthesis of a
wide variety of biologically active substances such
as steroid and polypeptide hormones, eicosanoids,
neurotransmitters, vasoactive peptides, growth fac-
tors and cytokines, but also its capacity to express
most of the receptors of these substances.3 Each of
these substances has varying degrees of pleiotropic
functions. By controlling growth, differentiation,
the synthesis of other signaling factors, immunity,
and contractile activity at the level of numerous
fetal and maternal targets, they participate in the
development of the fetoplacental unit and in the
adaptation by the maternal organism, primarily the
uterus, at the gestational state.
The concept of fetoplacental unit, elaborated in
the human species and up to now limited to bio-
synthetic, progesterone and estrogen pathways,4
has recently been enriched by the discovery of
other interactions. In the trophoblast, 11 [3-hydroxy-
steroid-dehydrogenase, which catalyzes the inter-
conversion of cortisol into cortisone, would appear
to play a role in triggering parturition. The de-
crease in the synthesis of placental cortisol would
lead, at the end of pregnancy, to the activation of
the fetal hypothalamic-pituitary-adrenocortical axis
and synthesis of fetal cortisol. This would have the
effect of accelerating pulmonary maturation of the
fetus and of contributing, along with other hor-
mones, to the production of placental corticotropin-
releasing hormone (CRH), one of the effects of
which is to activate uterine motility. This fetopla-
cental "dialogue," which begins early on in preg-
nancy, would reinforce the idea of the existence of
a close relationship between fetal development and
the duration of gestation in the human species and
in certain primates,s
Of all the organs, it is the placenta which has the
greatest species specificity in terms of its morpho-
logical, structural and functional characteristics.6
Indeed, there exist several ways of optimizing the
fetomaternal exchanges through the placenta. We
might thus raise the question as to whether the
species diversity noted in the mechanisms of the
onset of parturition might not, in part, be linked to
the mode of placentation (the human placenta is of
a hemochorial type).
At the fetomaternal interface, structures other
than the villous trophoblast are able to express a
certain number of biologically active substances
and their receptors: extravillous and invasive tro-
phoblast, amniotic and decidual cells, and immune
cells (macrophages, lymphocytes). The potentiali-
ties of expression of myometrial cells are also being
examined at present. It is within the intervillous
blood space, the circulation which is specific to the
human fetomaternal interface, that some of these
substances which control both the development of
the fetus and uterine activity are found at high
concentrations at the end of pregnancy. 7
In this context, which favors regulations of a
paracrine, autocrine and intracrine type, the role of
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each substance in the control of uterine activity is
difficult to evaluate. This situation is accentuated
at the site of placental insertion, where interactions
between fetal and maternal cells are established
which are both subtle and evolutive.8 Indeed, it is
in the human species that the invasion of uterine
tissue by trophoblast cells is the most extensive,
colonizing the wall of the spiral uterine arteries and
reaching the inner layer of the myometrium.
Although we are uncertain whether it was
chance alone which determined the diversity of the
placental structure and that of the fetomaternal in-
terface according to the species, these phenomena
which, in the human species are superimposed
upon classical endocrine activity, could be one of
the signs of evolution. In the pregnant woman, the
hypothesis of local action of signaling factors origi-
nate from intrauterine tissues in the control of uter-
ine motility would help to at least partly under-
stand why their placental production, like their
concentration in the maternal peripheral circula-
tion, are often impossible to correlate with the
maintenance of gestation, the triggering of labor
and parturition.
BIOCHEMICAL CHANGES IN THE UTERUS
AT THE END OF PREGNANCY.
INTEGRATIVE PROCESSES FOR
SIGNALING FACTORS
During the final weeks of pregnancy, biochemical
modifications affect the uterine cervix and the
myometrium. While the beginning of labor seems
to occur rather suddenly "maturation" processes
take place gradually, both at the level of the
smooth muscle fibers (predominant in the myome-
trium) and that of the extracellular matrix (pre-
dominant in the cervix). The latter dissociates,
which enables the cervix to dilate. Indeed, we note
an increase in hydration which might be linked to
that of hyaluronic acid and dispersion of collagen
fibers which may be connnected to variations in the
distribution of glycosaminoglycans and the release
of proteolytic enzymes by cervical myofibroblasts.
9
The presence of macrophages and polynuclears
may contribute, via release of lipid mediators and
of cytokines, to increasing the expression of metal-
loproteinases, with such alterations being similar to
those of an inflammatory reaction.1 These same
processes, in the myometrium, tend to favor inter-
cellular communications (gap junctions) and the ac-
cession of smooth muscle cells toward a highly ef-
fective contractile phenotype, as witnesses by the
characterization, in term myometrium, of isoforms
of "marker" proteins of this phenotype (o-actin,
desmin, SM1 and SM2 myosin heavy-chains) as
compared to the weak presence of non-muscular
isoforms. 11
As observed for other smooth muscle cells, it is
probable that such modifications affect interactions
between extracellular matrix and myometrial cells
via adhesion molecules (integrins, etc.), lz These
transmembrane glycoproteins, the assembly of
which is regulated by a small GTP-binding protein
Rho, interfere with signaling pathways and regu-
late cells morphology, migratory properties,
growth, differentiation, and contractility.
13
Another poorly defined aspect is that of para-
crine interactions of cervical myofibroblasts and
myometrial smooth muscle cells with the other
cells which are found in uterus at the end of preg-
nancy: those of the vascular system, and in particu-
lar microcirculation, and those of the immune sys-
tem (mast cells, eosinophils, neutrophils), which
are important sources of signaling factors.4 In con-
trast, we note the degeneration of nerve endings in
the human myometrium at term.
At the moment of parturition, control of the con-
tractile activity of the uterine muscle necessitates the
setting up of numerous powerful regulatory sys-
tems acting not only upon expression of signals but
also upon that of proteins of the signaling path-
ways: receptors, G proteins, effector proteins (en-
zymes, ionic channels, etc.) which modulate the
balance between the intracellular second messen-
gers. While inositol triphosphate (IP3) and calcium
initiate contraction, cAMP and cGMP induce re-
laxation. These intracellular messengers can also
control expression of inductible genes which help
to modify the cell phenotype and consequently the
responses to various stimuli.
In the human myometrium, the basic mecha-
nisms of contraction do not appear to greatly differ
from those of other smooth muscles, ls’6 The key
enzyme is the myosin light-chain kinase (MLCK)
which, when activated by the calcium-calmodulin
complex, phosphorylates the 20-kDa myosin light-
chain. In this phosphorylated form, myosin inter-
acts with actin and induces contraction. However,
when MLCK is itself phosphorylated by the pro-
tein kinases (PK) such as calcium-calmodulin-
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dependent PKII, PKC, PKA and PKG which are
respectively, AMPc- and GMPc-dependent, the ca-
pacity of MLCK to activate myosin and thus to
produce contraction decreases. The drop in intra-
cellular calcium (CaZ+i) leads to relaxation: dephos-
phorylated myosin, under the effect of a specific
phosphatase, thus becomes detached from actin.
While this schema appears to be well established in
vitro, it does not always appear to apply as well in
vivo. Moreover, the relative importance of the dif-
ferent regulatory pathways may vary according to
whether they involve spontaneous contractile ac-
tivity or that provoked by extracellular signals. Re-
cent studies have underscored the fact that the
streching of the muscle, which is very marked at
the end of pregnancy, could stimulate the expres-
sion and the activity of enzymes of the contractile
machinery, in particular by lowering the response
threshold of the MLCK to CaZ+i, which would en-
hance contraction. The existence of other regula-
tory pathways involving thin-filament binding pro-
teins (caldesmon and calponin) is merely suggested
in the myometrium.
Various specific ionic channels are expressed by
the myometrium. Calcium channels, the conduc-
tance of which can be activated by a variation in
transmembrane potential (VOC, or voltage-
operated channels) of the L (long-lasting) type or
of the T (transient) type, via attachment of a spe-
cific ligand (ROC, or receptor-operated channels)
or by a mechanical strain, 17 contribute to the in-
crease in CaZ+i. The latter can also arise from in-
tracellular sites whose storage capacity would in-
crease during gestation. The sarcoplasmic reticu-
lum, in close relationship with the caveolae of the
plasma membrane, is, in the myometrium, the
main site at which receptor proteins of inositol tri-
phosphate (IP3) and of ryanodine act as channels
enabling the calcium efflux necessary for contrac-
tion toward the cytoplasm. In contrast, at the level
of the plasma membrane and the sarcoplasmic re-
ticulum, several systems would contribute toward
lowering the Cae+i, in particular the Na/Ca ex-
changer and the Cae+/ATPases which play a major
role in the myometrium. These systems, which are
activated by cAMP, provoke relaxation. The im-
pact ofcGMP is much less evident, as is that of the
several cytosolic proteins which bind calcium.
Activation ofphospholipase C (PLC) leads to hy-
drolysis of phosphatidylinositol biphosphate (PIP2)
and to formation of two messengers, IP3 which mo-
bilizes CaZ+i and diacylglycerol (DAG), an activator
of PKC. This enzymatic system is the main path-
way of transduction used by the prostaglandins,
oxytocin, the otl-adrenergic agents and the endo-
thelins, to induce contraction in the human myo-
metrium at the term. 18’19 Endothelin-1, which in
vitro is as powerful a uterotonic agent as oxytocin,z
is the most efficient activator of PLC. el This action
is relayed by G proteins which are sensitive (Gi ?)
and insensitive (Gq/ll) to the pertussis toxin,zz
Only the endothelin receptors of the ETA type
coupled with PLC are involved in contractility,z3
The proportion of these receptors increases at the
end of pregnancy with respect to the ETu recep-
tors,z6 whose function in the myometrium remains
unknown.
PGEz and PGFzot, although they could bind to
different receptors, stimulate PLC activity via a
Gq/ll protein. Another G protein (Gi ?)could be
implicated in the activation of the channels (ROC)
by the prostaglandins,zs The result would be a pre-
liminary increase in CaZ+i necessary for later acti-
vation by PGFzot of a CaZ-dependent PLC. 19 Con-
versely at the level of the uterine cervix, PGE 2, a
powerful stimulator of cAMP synthesis by the cer-
vical myofibroblasts, may play a crucial role in re-
laxation and in the processes of maturation ob-
served at the end of pregnancy.26 Like the endo-
thelins, oxytocin activates the myometrial PLC via
a Gq/11 protein and a G (Gi ?) protein,27 though no
preliminary influx of Ca2+ is necessary as in the
case of PGFzot. Nevertheless, the ROC channels
could enable oxytocin to increase the Cae+i. The
coupling of the oxytocin receptor to a Gh protein
has recently been revealed in the human myome-
trium,z8 It is now known that it is a family of iso-
forms, the PLC-[3, which is implicated in the acti-
vation of the receptors to seven transmembrane
domains coupled to G proteins. Three isoforms,
131, 132 and 133, are involved in the contraction ef-
fect of oxytocin in the human myometrium. An-
other family of isoforms, PLC-y, whose mode of
activation differes from that of PLC-13, also leads to
mobilization of Cae+i. In the human myometrium,
the EGF receptor, which possesses tyrosine kinase
activity, stimulates the PLC-y via phosphoryla-
tion,z9,z The PLC-[3 and PLC-y activities would
be subject to different negative retrocontrol
mechanisms, generally involving PKC for PLC-[3
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and PKA for PLC-y, but this aspect has not yet
been elucidated in the human gravid myometrium.
In addition, oxytocin and very likely the CRH
and endothelins stimulate phospholipase Az activ-
ity, leading to synthesis of endogenous prostaglan-
dins in the human gravid myometrium. The latter,
in turn, stimulate PLC-13, thereby amplifying their
direct effects upon this enzymatic pathway.
In the course of the third trimester of pregnancy,
a phenomenon ofheterologous desensitization to the re-
laxing agents: 132-adrenergic and prostaglandins,
activators of adenylyl cyclase, has been revealed in
the human myometrium.31,32
This mechanism of desensitization also has
bearing on activation of adenyly cyclase by the
CRH, in the human term myometrium. Like the
catecholamines and prostaglandins, the alteration
in the coupling of certain of the CRH receptors to
the catalytic component of adenylyl cyclase via a
Gs protein has been observed.33 In the human
myometrium at term, other mechanisms contribute
to lowering the cAMP concentration. Coupling of
the adrenergic 132 and or2 receptors to an adenylyl
cyclase inhibiting Gi protein has been ob-
served.31,34 The decrease in the cAMP capacities
for synthesis observed at the end of pregnancy
could still be accentuated at the level of its enzy-
matic degradation. A family of isoforms of (PDE)
phosphodiesterase cyclic nucleotide which specifi-
cally degrades cAMP at high affinity, is abundant
in the human myometrium at the end of preg-
nancy.3s This hormone-sensitive PDE4 activity is
the point of impact of pharmacologic agents with
myorelaxing and anti-inflammatory properties.
36
The nitric oxide (NO) pathway could be a link
with the mechanisms responsible for maintenance
of the quiescent state in the uterus during preg-
nancy. Indeed, its use in the treatment of threat-
ened premature birth has been proposed. The NO
synthase system, which is very active in the gravid
human uterus, decreases at the time of labor. How-
ever, the role of cGMP in myometrial relaxation
induced by NO has not been entirely elucidated,a7
Other substances classically identified as growth
factors (IGFs, EGF) and gonadotropins (hCG),
whose receptors have recently been revealed in the
human myometrium, also appear to be regulators of
contraction.8,9 This action would be due to stimu-
lation of eicosano’l’d production and/or to the fact
that the multiple signals use common or interacting
signaling pathways. Among various kinases, which
play a role in the signaling cascade, the role ofMAP
kinase and tyrosine kinases needs to be clarified.4
Because of these phenomena of "cross-talk,"
the response to a given signal will vary considerably
depending on the other signals present and will be
an activating or an inhibiting response, probably
synergic rather than additive. Moreover, it is now
clear that differential control of the expression and
the activity of the different protein isoforms, which
intervene at each stage of the transmission of the
signal, i.e., receptors, G proteins, enzymatic effec-
tors, etc., ensure specificity and contribute to the
diversity of the responses in terms of contractility.
We are now seeking to better understand which
isoforms are determinant in the point of no return
which, in the human myometrium at term, charac-
terizes the onset of labor, and which factors control
their expression and function. From this point of
view, the steroid hormones hold a special position
among the effectors of uterine activity.
It is classically considered that progesterone,
due to its relaxing properties, is responsible for the
state of hypocontractility of the uterus during preg-
nancy, in opposition to the contracting effect of
17[3-estradiol. The 17[3-estradiol/progesterone ra-
tio, which is higher in the human myometrium at
term than at the beginning of pregnancy, raises the
question of the manner in which agonist and an-
tagonist relationships are exerted between these
two steroids, whether their effects upon uterine
contraction are genomic or non-genomic.
In the myometrium as in the cervix, the steroid
hormone receptors exert their pleiotropic effects by
modulating the transcription of a number of target
genes which code for the structural and contractile
proteins, for enzymatic proteins responsible for the
production of other direct or indirect effectors of
uterine activity (prostaglandins, cytokines, etc.), for
degradation proteins (collagenases, proteases, pep-
tidases, phospholipases, etc.) and for various other
proteins implicated in intracellular transduction
(ionic channels, receptors, G proteins, etc.) and in-
tercellular communication (connexins of the gap
junctions). Results reported concerning the evolu-
tion of steroid hormone receptors in the gravid hu-
man myometrium are currently highly controver-
sial. The most recent of these indicate that these
receptors are present in the smooth muscle and the
vessels of the myometrium at the end of preg-
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nancy, and that only the progesterone receptors de-
crease during labor, whether or not it is prema-
ture.41 It should be pointed out that up to now no
study has been made in human myometrium of the
evolution especially during pregnancy of the iso-
forms of progesterone and estrogen receptors, re-
cently revealed in other tissues, which could be
associated with different functions. The responses
of genes modulated by the steroid hormones often
necessitate the interaction of their receptors with
other transcription factors. We can thus understand
how difficult it is to dissociate the proper effects of
the steroid hormones, whether they be direct or
indirect, from those of the other hormonal signals.
This difficulty is even greater due to the complex-
ity of the relationship between the steroid hor-
mones and their receptors, which can partly explain
their complementarity and their antagonism. In the
myometrium, estrogens are necessary for synthesis
of the progesterone receptors, while progesterone
inhibits the expression of estrogen receptors and
that of its own receptors. Like other nuclear recep-
tors referred to as "orphans," the steroid hormone
receptors can be operational in the absence of a
ligand.
In general, the effects of progesterone are di-
rectly opposite those of the estrogens, which in-
duce the synthesis of signals and of proteins which
intervene in contraction. Nevertheless, this is not
always the case: the presence of progesterone is, in
fact, required during the induction of the synthesis
of certain ionic channels by 1713-estradiol. Consid-
ering that progesterone favors the expression of im-
munosuppressive cytokines during gestation, it re-
mains to clarify what happens with the Th2/Thl
cytokine balance in the different cell populations
of the uterus at time of parturition.
There unquestionably exist, in the myometri-
urn, rapid non-genomic effects of steroid hormones
which to a certain extent interfere via second mes-
sengers with the genomic effects. Although the no-
tion of membrane receptors of steroid hormones
remains subject to controversy, progesterone de-
creases and 17[3-estradiol increases the fluidity of
the plasma membranes.These modifications could
both influence the organization and function of the
membrane proteins and modulate the flexibility
necessary for morphological changes which the
smooth uterine fiber undergoes during the contrac-
tion-relaxation cycle. Hyperpolarizing progester-
one, by inhibiting the VOC type L channels re-
sponsible for the entry of calcium into the myome-
trial cell and, consequently, for MLCK activity,
relaxes the uterine muscle. Other calcium-
calmodulin-dependent enzymes can also be inhib-
ited, among them a family of phosphodiesterase
isoforms which degrade cAMP and cGMP, both of
which are involved in relaxation. In the human spe-
cies, while parturition occurs with high myometrial
levels of progesterone, recent experiments none-
theless suggest that the relaxing effect of proges-
terone upon the smooth uterine muscle is neutral-
ized at the start of labor, or else is reversed during
parturition.4z,43
It is clearly evident at the present time that in
the human species, parturition is conditioned by
the progressive passage of the myometrium in a
quiescent state, where the functionality of the ad-
enylyl cyclase system predominates, toward other
transduction pathways such as that involving phos-
pholipase C, the activation of which leads to mo-
bilization of CaZ+i and to contraction. Such results,
when compared to those obtained in animals, un-
derscore the specificity of the species in terms of
the response of these enzymatic systems to hor-
monal signals in the pregnant myometrium. The
impact of modifications observed in parallel at the
level of the extracellular matrix upon phenotypic
evolution of the uterine smooth fiber and its inter-
actions with other uterine cells must be taken into
account.
However, while all the substances present at the
fetomaternal interface play a role in the uterine
motility taking place during the different phases of
parturition, none seems to play the initial role in
setting it off. For example, prostaglandins, which
exert a coordinated, efficient effect upon the myo-
metrium and the uterine cervix, are widely used to
artificially induce labor, but no element enables us
to definitively state that they play a determing role
in the physiological onset of parturition.
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